Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Recurrence 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Glioma 1Diffuse Intrinsic Pontine Glioma 1Central Nervous System Neoplasms 1

Interventions

Temozolomide 3Bevacizumab 3Re-Irradiation 2Nivolumab 2Irinotecan 2Cetuximab 2ribociclib 1pembrolizumab 1lutetium Lu 177 dotatate 1dostarlimab 1dipinacoline glutamate 1dinutuximab 1cemiplimab 1abemaciclib 1Vorinostat 1Vincristine 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Radiotherapy 1Mebendazole 1Maintenance 1Granulocyte-Macrophage Colony-Stimulating Factor 1Fluid Therapy 1Eflornithine 1Congresses as Topic 1Carboplatin 1CBLC137 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Diffuse Intrinsic Pontine Glioma × Maintenance × Clear all
NCT03690869 2025-04-08

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Regeneron Pharmaceuticals

Phase 1/2 Terminated
57 enrolled 31 charts
CNS

Diffuse Intrinsic Pontine Glioma, Glioma, Recurrence, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡